Search
On November 10, 2025, Insilico Medicine unveiled a strategic partnership with Eli Lilly aimed at advancing drug development, with the total value of this collaboration soaring past $100 million. In this joint effort, the two entities will harness the power of Insilico Medicine's AI-driven drug discovery platform, Pharma.AI, and pair it with Eli Lilly's extensive expertise in drug development and disease research. By doing so, they aim to collectively expedite the discovery and development of groundbreaking therapeutic solutions.
As part of this agreement, Insilico Medicine is set to receive a comprehensive package of benefits exceeding $100 million. This includes an initial upfront payment, milestone payments tied to research and development progress, as well as royalties stemming from the future commercialization of drugs developed through this collaboration.
-
C114 Communication Network -
Communication Home
